Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline ... especially the recently approved DMD gene therapy Elevidys. Year to date, Sarepta Therapeutics ...

Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.